An affinity threshold for maximum efficacy in anti-PD-1 immunotherapy

An affinity threshold for maximum efficacy in anti-PD-1 immunotherapy

Monoclonal antibodies targeting the programmed cell death protein 1 (PD-1) remain the most prevalent cancer immunotherapy both as a monotherapy and in combination with additional therapies. Despite the extensive success of anti-PD-1 monoclonal antibodies in the clinic, the experimental relationship...

Full description

Bibliographic Details
Main Authors: Sarah C. Cowles, Allison Sheen, Luciano Santollani, Emi A. Lutz, Brianna M. Lax, Joseph R. Palmeri, Gordon J. Freeman, K. Dane Wittrup
Format: Article
Language:English
Published: Taylor & Francis Group 2022-12-01
Series:mAbs
Subjects:
PD-1
antibody
affinity
pharmacokinetic modeling
cancer immunotherapy
Online Access:https://www.tandfonline.com/doi/10.1080/19420862.2022.2088454

Internet

https://www.tandfonline.com/doi/10.1080/19420862.2022.2088454

Similar Items